HERCULES, CA -- (Marketwire) -- 10/23/09 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has signed an agreement to acquire certain diagnostic businesses of Biotest AG for 45 million euros. The terms of the agreement were not disclosed at this time. The transaction is subject to certain closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2010.
Based in Germany, Biotest develops, manufactures, and markets pharmaceutical, biotherapeutic, and diagnostic products. Integrating Biotest's diagnostic business into Bio-Rad's product portfolio will broaden the company's offering in the area of immunohematology and provide Bio-Rad access to the U.S. markets with a full range of products. Biotest is listed on the SDAX on the Frankfurt Stock Exchange and has more than 2,000 employees worldwide.
"Biotest has an impressive reputation for offering quality products and customer service, and we believe their array of products in the area of immunohematology will fit in well with Bio-Rad's existing diagnostics business," said Norman Schwartz, Bio-Rad President and CEO.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.
For more information contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia
Corporate Communications
510-724-7000
http://ih.advfn.com/p.php?pid=nmona&cb=1256614851&article=40031628&symbol=NY%5EBIO
Recent BIO News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 10:37:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 05:42:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 09:50:32 PM
- Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group • Business Wire • 05/30/2024 01:00:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference • Business Wire • 05/23/2024 08:15:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/09/2024 08:30:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:38:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:31:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:18:26 PM
- Bio-Rad Reports First-Quarter 2024 Financial Results • Business Wire • 05/07/2024 08:15:00 PM
- Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference • Business Wire • 05/01/2024 01:00:00 PM
- Bio-Rad Announces Life Science Group Management Changes • Business Wire • 04/26/2024 12:30:00 PM
- Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • Business Wire • 04/18/2024 01:00:00 PM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Bio-Rad’s Chief Operating Officer Andrew Last to Retire • Business Wire • 04/10/2024 08:15:00 PM
- Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer • Business Wire • 03/20/2024 12:30:00 PM
- Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day • Business Wire • 02/22/2024 09:30:00 PM
- Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results • Business Wire • 02/15/2024 09:15:00 PM
- Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 • Business Wire • 01/24/2024 10:00:00 PM
- Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference • Business Wire • 01/02/2024 09:15:00 PM
- Bio-Rad Reports Third-Quarter 2023 Financial Results • Business Wire • 10/26/2023 08:15:00 PM
- Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 • Business Wire • 10/05/2023 12:30:00 PM
- Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference • Business Wire • 08/28/2023 08:15:00 PM
- Bio-Rad Reports Second-Quarter 2023 Financial Results • Business Wire • 08/03/2023 08:15:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM